BD a leading global medical technology company, announced the global commercial release of new configurations of cell analyzers featuring breakthrough spectral and real-time cell imaging technologies, enabling more labs in academia, pharma and biotech – across scales, needs and budgets – to advance ...

Upsher-Smith Laboratories, LLC  announced the launch of KYMBEE™ (deflazacort) Tablets, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Manufactured by Upsher-Smith in Minnesota, KYMBEE™ is the only deflazacort backed by Upsher-Smith's Promise ...

Citius Oncology, Inc. the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult ...

Centinel Spine®, LLC the leading global medical device company focused exclusively on treating cervical and lumbar spinal disease with the most complete and clinically-proven total disc replacement (TDR) technology platform in the world (prodisc®),  announced a significant coverage advancement for ...

SmartSkin Technologies, a leader in pharmaceutical manufacturing intelligence, announced the availability of SmartSkin Seal Assurance, a breakthrough solution that gives pharmaceutical manufacturers real-time visibility into seal tightness leading to Container Closure Integrity across vial and ...

AbbVie announced primary results from the pivotal Phase 3 ECLIPSE study, evaluating the safety, efficacy and tolerability of atogepant (60 mg) versus placebo for the acute treatment of migraine in adults (with or without aura).

The study met its primary and key secondary endpoints, with ...